Saturday, October 3, 2026

Ripple On Bearish Momentum: 0% Down In The Last 6 Hours

ViaNews Editorial Team

December 27, 2020

Ripple On Bearish Momentum: 0% Down In The Last 6 Hours

Ripple is currently on bearish momentum. At 11:09 EST on Sunday, 27 December, Ripple is at $0.30 and down by 0% in the last 6 hours.

Ripple Range

Over the last six hours, Ripple's higher value was $0.30 and the lower value was $0.28.

Over the last twelve hours, Ripple's higher value was $0.30 and the lower value was $0.28.

About Ripple's daily highs and lows, it's 7.143% up from its trailing 24-hour low of $0.28 and 3.226% down from its trailing 24-hour high of $0.31.

Regarding Ripple's yearly highs and lows, it's 160.643% up from its 52-week low and 60.938% down from its 52-week high.

Volatility

Ripple's last day and last week average volatility is a negative 7.94% and a positive 13.52%, respectively. Ripple's high and low amplitude percentage in the last week was 27.29%.

News about Bitcoin

 michael saylor, the CEO who turned a software company into a Bitcoin company. According to Bloomberg Quint on Thu Dec 24, "Then, as Bitcoin ran up, it bought more, and the stock has now soared thanks to the bet. ", "This past summer, the business intelligence software company MicroStrategy made waves when it put some of its extra cash into Bitcoin. "

Bitcoin rally has already outlasted 2017 run. According to The Wall Street Journal on Thu Dec 24, "Bitcoin bulls say the money fueling this year's rally is coming from more reliable sources than past rallies. "

Bitcoin crushes doubters as 224% rally proves it’s here to stay. According to Bloomberg Quint on Thu Dec 24, "There has been no substantial progress made on Bitcoin as a unit of exchange. ", "Since Bitcoin's market capitalization reached $1 billion in March 2013, there have been two cycles of spikes to record highs, followed by drawdowns of more than 80%. "

Luxxfolio to acquire 590 Bitcoin miners. According to Business Insider on Thu Dec 24,

Bitcoin surges to fresh record high and looks set to break the $25,000 level: 'merry bitmas'. According to Business Insider on Fri Dec 25, "However, Bitcoin investors - known for their unquenchable optimism - think this is just the start.", "Known as the leading cryptocurrency, Bitcoin has been a surprise success during the pandemic, quickly becoming a competitor to gold in some portfolios."

Bitcoin miners in nordic region get a boost from cheap power. According to Bloomberg Quint on Sun Dec 27, ""We have seen a notable up-tick in investor appetite for Bitcoin mining opportunities in Norway," said Tyler Page, a business developer at Bitfury. ", "The resulting glut in the most important raw material for making the virtual coins coincided with a year when the price of Bitcoin tripled."

Bitcoin faces regulatory scrutiny after record-breaking rally. According to Bloomberg Quint on Sun Dec 27, "Janet Yellen, who's been nominated to serve as Treasury secretary in Biden's administration, has in recent years cautioned investors over Bitcoin, saying it was a "highly speculative asset" and "not a stable store of value." A representative didn't immediately return a request seeking comment.", ""What's happening now -- and it's happening faster than anyone could ever imagine -- is that Bitcoin is moving from a fringe esoteric asset to the mainstream," said Matt Hougan, chief investment officer of Bitwise Asset Management. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com